Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02177786 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 334
- Enrollment target
NCT02177786 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 334 participants.
The verdict
NCT02177786, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 334 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the effect of selonsertib (formerly GS-4997) on estimated glomerular filtration rate (eGFR) decline in participants with diabetic kidney disease (DKD). Participants will be randomized with a 1:1:1:1 allocation to receive 1 of 3 doses of selonsertib (2 mg, 6 mg, or 18 mg) or matching placebo.
Interventions
- DRUG Selonsertib
- DRUG Placebo to match selonsertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 334 participants |
| Start Date | 2014-06 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02177786
The ClinicalTrials.gov registry entry for NCT02177786 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 334 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Selonsertib is the first listed.
NCT02177786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02177786 about?
NCT02177786 is a clinical study titled "Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease". The primary objective of this study is to determine the effect of selonsertib (formerly GS-4997) on estimated glomerular filtration rate (eGFR) decline in participants with diabetic kidney disease (DKD). Participants will be randomized with a 1:1:1:1 allocation to receive 1 of 3 doses of selonsertib...
What is the current status of trial NCT02177786?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 334 participants. The study started on 2014-06. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02177786?
The interventions under investigation include: Selonsertib (DRUG), Placebo to match selonsertib (DRUG).
Who is sponsoring clinical trial NCT02177786?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.